World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
106
Citations
59505
World Ranking
6384
National Ranking
3402

Overview

Hyman B. Muss is affiliated with the University of North Carolina at Chapel Hill in the United States. Their research primarily focuses on medicine, with considerable work in oncology, pulmonary and respiratory medicine, physiology, geriatrics and gerontology, and cancer research. Over their career, they have contributed extensively to the study of cancer and aging, with particular attention to cancer survivorship and care, frailty in older adults, nutrition and health in aging, cancer treatment and pharmacology, breast cancer treatment studies, cancer-related cognitive impairment studies, and health systems including economic evaluations and quality of life.

Their recent publications demonstrate a focus on aging and cancer treatment outcomes. Notable papers include:

  • Older adult participation in cancer clinical trials: A systematic review of barriers and interventions, 2020, CA A Cancer Journal for Clinicians
  • Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer, 2021, Journal of Clinical Oncology
  • Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14,324 women in 16 trials, 2023, The Lancet
  • p16 a biomarker of aging and tolerance for cancer therapy, 2020, Translational Cancer Research
  • Accelerated aging among childhood, adolescent, and young adult cancer survivors is evidenced by increased expression of p16INK4a and frailty, 2020, Cancer

They frequently publish in a range of venues, including:

  • UNC Libraries
  • Journal of Clinical Oncology
  • The Oncologist
  • Journal of Geriatric Oncology
  • Cancer

Muss collaborates regularly with several other researchers. Frequent coauthors include Allison M. Deal, Kirsten A. Nyrop, Grant R. Williams, Lisa A. Carey, and Harvey Jay Cohen.

Best Publications

  • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

    O. Abe;R. Abe;K. Enomoto;K. Kikuchi

  • A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

    Paul E. Goss;James N. Ingle;Silvana Martino;Nicholas J. Robert

  • Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741

    Marc L. Citron;Donald A. Berry;Constance Cirrincione;Clifford Hudis

  • Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer

    I. Craig Henderson;Donald A. Berry;George D. Demetri;Constance T. Cirrincione

  • Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17

    Paul E. Goss;James N. Ingle;Silvana Martino;Nicholas J. Robert

  • c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer

    Hyman B. Muss;Ann D. Thor;Donald A. Berry;Timothy Kute

  • Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343

    Kevin S. Hughes;Lauren A. Schnaper;Jennifer R. Bellon;Constance T. Cirrincione

  • Cellular senescence promotes adverse effects of chemotherapy and cancer relapse

    Marco Demaria;Marco Demaria;Monique N. O'Leary;Jianhui Chang;Lijian Shao

  • Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

    Marcus E. Randall;Virginia L. Filiaci;Hyman Muss;Nick M. Spirtos

  • Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

    Donald A. Berry;Constance Cirrincione;I. Craig Henderson;Marc L. Citron

  • Dose and Dose Intensity as Determinants of Outcome in the Adjuvant Treatment of Breast Cancer

    Daniel R. Budman;Donald A. Berry;Constance T. Cirrincione;I. Craig Henderson

  • Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840

    Andrew D. Seidman;Donald Berry;Constance Cirrincione;Lyndsay Harris

  • Racial Differences in Survival From Breast Cancer: Results of the National Cancer Institute Black/White Cancer Survival Study

    J. William Eley;Holly A. Hill;Vivien W. Chen;Donald F. Austin

  • erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer

    Ann D. Thor;Ann D. Thor;Donald A. Berry;Daniel R. Budman;Hyman B. Muss

  • Breast Cancer Follow-Up and Management After Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline Update

    James L. Khatcheressian;Patricia Hurley;Elissa Bantug;Laura J. Esserman

  • Developing a Cancer-Specific Geriatric Assessment: A Feasibility Study

    Arti Hurria;Supriya Gupta;Marjorie Zauderer;Enid L. Zuckerman

  • Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

    Paul E. Goss;James N. Ingle;Kathleen I. Pritchard;Nicholas J. Robert

  • American Society of Clinical Oncology 2006 Update of the Breast Cancer Follow-Up and Management Guidelines in the Adjuvant Setting

    James L. Khatcheressian;Antonio C. Wolff;Thomas J. Smith;Eva Grunfeld

  • Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline

    Hope S. Rugo;R. Bryan Rumble;Erin Macrae;Debra L. Barton

  • Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer

    Hyman B. Muss;Hyman B. Muss;Donald A. Berry;Constance T. Cirrincione;Maria Theodoulou

Frequent Co-Authors

Bayard L. Powell
Bayard L. Powell Wake Forest University
Virginia J. Howard
Virginia J. Howard University of Alabama at Birmingham
Donald A. Berry
Donald A. Berry The University of Texas MD Anderson Cancer Center
Eric P. Winer
Eric P. Winer Yale University
Brenda K. Edwards
Brenda K. Edwards National Institutes of Health
Larry Norton
Larry Norton Memorial Sloan Kettering Cancer Center
Pelayo Correa
Pelayo Correa Vanderbilt University
Harvey J. Cohen
Harvey J. Cohen Duke University
Ralph J. Coates
Ralph J. Coates Centers for Disease Control and Prevention
Robert J. Kurman
Robert J. Kurman Johns Hopkins University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're considering a career in medicine, there are alternative online degrees and pathways that can prepare you for key roles in healthcare. Many students look at programs like a health administration degree online to build expertise in managing healthcare operations, policy, and leadership. These degrees often pave the way for administrative and managerial roles in hospitals or clinics.

For those seeking advanced leadership roles, pursuing one of the cheap mha programs (Master of Healthcare Administration) is a cost-effective way to develop specialized business and healthcare skills. Similarly, for nurses aiming for top-level clinical or executive positions, exploring the cheapest dnp (Doctor of Nursing Practice) programs can offer both flexibility and affordability.

Pharmacists are also in high demand, and enrolling in an online pharmacy school cost can be a key consideration for aspiring professionals who want to obtain a PharmD without excessive student debt.

With the right online degree, you can take the next step in your healthcare career while balancing work, study, and financial priorities.

Best Scientists Citing Hyman B. Muss

Trending Scientists

Recently Published Articles